Journal
ACTA PHARMACOLOGICA SINICA
Volume 41, Issue 1, Pages 101-109Publisher
NATURE PUBL GROUP
DOI: 10.1038/s41401-019-0294-9
Keywords
human lung adenocarcinoma; Cu-64-NOTA-mAb109; antibody production; positron-emission tomography (PET) imaging; NIRF imaging
Funding
- National Natural Science Foundation of China [81671733, 81571705]
- Natural Science Foundation of Beijing Municipality [7171002]
- Beijing Nova program [Z171100001117020]
- Young Top-Notch Talents Team program of Beijing Excellent Talents Funding [2017000021223ZK33]
Ask authors/readers for more resources
Monoclonal antibodies are believed to be magic bullets and hold great potential for lots of biological process. About 100 mu g of mAb109 was expressed in 5x10(6) cells after 10 days' immunization. Cu-64-NOTA-mAb109 was synthesized with the specific activity of 0.74MBq/mu g and high in vitro stability. The binding affinity of Cu-64-NOTA-mAb109 in A549 cells was determined to be 29.64nM. Cu-64-NOTA-mAb109 displayed prominent tumor accumulation from 2h to 60h p.i. (9.34 +/- 0.67 %ID/g). NIRF imaging of Cy5.5-mAb109 showed high accumulation till 9 days p.i., while tumors nearly can not be observed in negative groups, which was confirmed by autoradiography. Immunohistological study confirmed that mAb109 had strong and specific capacity to bind lung adenocarcinoma (concentration to 58nM). Our study demonstrated mAb109 was a new platform for the development of novel agent for lung adenocarcinoma noninvasive imaging. The resulted Cu-64-NOTA-mAb109/Cy5.5-mAb109 show favorable imaging properties/specificity for A549 tumor and high sensitivity to human lung adenocarcinoma tissues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available